Protara Therapeutics to Present at Upcoming Virtual Investor Conferences
Protara Therapeutics (Nasdaq: TARA) has announced its participation in two virtual investor conferences.
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Rhea-AI Summary
Protara Therapeutics (Nasdaq: TARA) has announced its participation in two virtual investor conferences. The first is the Guggenheim Healthcare Talks 2021 Oncology Days, scheduled for February 11, 2021, at 9:30 AM ET. The second event is the Cowen 41st Annual Health Care Conference on March 3, 2021, at 1:20 PM ET. Both presentations will be accessible via the Events and Presentations section of Protara's website and archived for 90 days. Protara focuses on innovative therapies for cancer and rare diseases, notably TARA-002 for bladder cancer and IV Choline Chloride for liver disease.
Details
News Market Reaction – TARA
The recorded move for TARA in the trading session of this news was +1.39%.
Data tracked by StockTitan Argus. Session date unavailable.
AI-generated analysis. How Rhea-AI works. Not financial advice.
NEW YORK, Feb. 04, 2021 (GLOBE NEWSWIRE) -- Protara Therapeutics, Inc. (Nasdaq: TARA), a clinical-stage company developing transformative therapies for the treatment of cancer and rare diseases with significant unmet needs, today announced that management will present at two upcoming virtual investor conferences:
- Guggenheim Healthcare Talks 2021 Oncology Days on Thursday, February 11, 2021 at 9:30am ET
- Cowen 41st Annual Health Care Conference on Wednesday, March 3, 2021 at 1:20pm ET
A webcast of the fireside chat presentations can be accessed by visiting the Events and Presentations section of the Company’s website: https://ir.protaratx.com. The webcasts will be archived on the Company’s website for 90 days following the presentations.
About Protara Therapeutics, Inc.
Protara is committed to identifying and advancing transformative therapies for people with cancer and rare diseases with limited treatment options. Protara’s portfolio includes its lead program, TARA-002, an investigational cell-based therapy being developed for the treatment of non-muscle invasive bladder cancer and lymphatic malformations, and IV Choline Chloride, an investigational phospholipid substrate replacement therapy for the treatment of intestinal failure-associated liver disease. For more information, visit www.protaratx.com.
Company Contact:
Justine O'Malley
Protara Therapeutics
Justine.OMalley@protaratx.com
646-817-2836
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.